PREVAIL study.

Trial name or title	PREVAIL study ‐ PREVenting infection using Antimicrobial Impregnated Long lines
Methods	Unblinded, 2‐arm randomised controlled trial to determine the effectiveness and cost‐effectiveness of antimicrobial impregnated (with rifampicin and miconazole) long lines (termed peripherally inserted central venous catheters, or AM‐PICC) compared with standard PICC (S‐PICC) for reducing BSI
Participants	Infants receiving a PICC
Interventions	Antimicrobial impregnated (with rifampicin and miconazole) peripherally inserted central venous catheters (AM‐PICC) compared with a standard PICC (S‐PICC)
Outcomes	Time to first BSI based on a positive blood culture (including fungal BSI) taken between 24 hours after randomisation and 48 hours after removal As part of the primary endpoint there will be 2 sensitivity analyses: A sensitivity analysis confined to clinically serious BSI defined by positive culture and the infant is treated for > 72 hours with intravenous antibiotics or dies during treatment Time to first BSI based on a positive blood culture (including fungal BSI) taken between 24 hours after PICC insertion and 48 hours after removal
Starting date	The study will run from December 2014 to August 2017
Contact information	The study will run from 18 neonatal units in the UK. The lead centre will be Bradford Teaching Hospitals NHS Foundation Trust. The study will be co‐ordinated through the Medicines for Children Clinical Trials Unit, University of Liverpool Contact details; Prof. Ruth Gilbert, MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK; email: r.gilbert@ucl.ac.uk
Notes	Funded by National Institute for Health Research Health Technology Assessment Programme ‐ Health Technology Assessment (UK). ISRCTN81931394

BSI: bloodstream infection; PICC: peripherally inserted central catheter.